Long-term effect of persistent smoking on the prognosis of Chinese male patients after percutaneous coronary intervention with drug-eluting stent implantation  by Liu, Jun et al.
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Objectives:  This  study  aimed  to survey  the  adherence  to  smoking  cessation  and assess  the  inﬂuence  of
persistent  smoking  on  the  prognosis  in male  patients  after  drug-eluting  stent  (DES)  implantation.
Methods: The  smoking  status  at the  time  of  the index  procedure  and  at follow-up  was  surveyed  in  656 male
patients  undergoing  successful  percutaneous  coronary  intervention  (PCI)  with  DES  in our  center.  These
patients  were  divided  into  three  groups,  based  on  their  smoking  status:  nonsmokers  (n =  226), quitters
(n  =  283),  and  persistent  smokers  (n =  147).  Major  adverse  cardiac  and  cerebrovascular  events  (MACCE)
during  the  follow-up  period  were  carefully  recorded  and  their relationship  with  smoking  status  was
investigated  for  24–41  months.
Results: Among  656  patients  who  were  followed  up for 27.24  ±  6.33  (7–40)  months,  430 of  them  were
smokers  (65.5%)  at the  index  procedure.  A  total  of  147 patients  (22.4%)  who  continued  to  smoke,
accounted  for 34.2%  of  smokers  at the time  of  PCI.  Persistent  smokers  and  quitters  were  more  likely  to
be  young  (p < 0.001)  than  nonsmokers,  persistent  smokers  had  more  dyslipidemia  (p =  0.005),  and  fewer
took  aspirin  (p = 0.016)  and  statins  (p =  0.045)  than  quitters  and  nonsmokers.  Weight gain  was  greater
for  quitters  (p  < 0.016)  than  for  nonsmokers.  The  incidence  of all-cause  death  (6.1% v.s.  1.8%  and  1.1%,
p  =  0.004)  and  MACCE  (15.0%  vs  7.1% and  5.3%, p =  0.002)  in  persistent  smokers  were  signiﬁcantly  higher
than  those  in nonsmokers  and  quitters.  Multiple  regression  analysis  showed  that  persistent  smoking  was
a  signiﬁcantly  determinant  factor  for all-cause  death  [hazard  ratio  (HR)  =  2.432, 95% conﬁdence  interval
(CI)  1.170–5.054;  p  < 0.017]  and  MACCE  (HR  =  1.519,  95%  CI  1.049–2.200;  p  = 0.027).
Conclusions: This  is  the  ﬁrst  follow-up  report  about  the long-term  effect  of  persistent  smoking  in  Chinese
male  patients  after  DES  implantation.  Our  ﬁndings  strongly  indicate  that  poor adherence  to  smoking
actor
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Cigarette smoking has been well-known to play an important
ole in the occurrence and development of coronary heart dis-
ase (CHD) [1–10]. China is the largest producer of tobacco in the
orld, and approximately 30% of the world’s cigarettes are con-
umed by China’s 350 million smokers. In 2002, the prevalence of
ctive smoking in the population aged 15 years and older was 66.0%
n men  and 3.1% in women. In clinical practice, although smoking
essation is strongly advocated after coronary revascularization,
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some patients tend to think that their diseases have been cured,
especially when they could not feel disease or they seem not to
have disease phenotype. Therefore, it becomes difﬁcult for them
to adhere to the complete cessation of smoking after discharge,
even if they had stopped smoking during hospitalization, which
may cause severe adverse clinical events. Furthermore, most of pre-
vious studies mainly focused on the inﬂuence of smoking status at
the time of PCI on clinical prognosis [6–10]. Some investigations
about the effect of smoking on clinical outcomes after PCI have been
performed during the pre-drug-eluting stent (DES) era [11–17].
Importantly, more and more DES have been deployed in the real
world [18–21]. However, to date, the impact of smoking status
in Chinese patients undergoing successful PCI with DES deploy-
ment remains unclear. Thus, it becomes necessary to investigate
the major effects of smoking status in Chinese patients undergoing
successful PCI with DES. Therefore, the aim of the present study is
vier Ltd. All rights reserved.
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o survey the adherence to smoking cessation and investigate the
ssociation between smoking status at follow-up and the long-term
linical outcome in these Chinese patients.
ethods
tudy populations
A  total of 1200 consecutive patients with CHD, who were
dmitted to Zhengzhou University People’s Hospital from January
009 to June 2010, were prospectively registered. Complete base-
ine data were available for 1173 of those patients (97.75%). PCIs
ere performed successfully in 1162 patients (96.83%), whereas 11
0.92%) patients did not experience successful PCI and 269 patients
22.42%) were lost during follow-up. As only 4 female smokers were
ound in our study, 237 female patients (19.75%) were also excluded
hen analyzing data at the end of the study. Thus, 656 patients
ere enrolled and investigated in the present study. All patients
ere given written informed authorizations for the release of all
uch information.
PCI  was performed using standard techniques. The angiographic
uccess of PCI was deﬁned as a minimum diameter stenosis of
10% (with an optimal goal of as close to 0% as possible) of
arget lesion after DES deployment, resulting in ﬁnal thromboly-
is in myocardial infarction ﬂow grade 3 without occlusion of a
igniﬁcant side branch, ﬂow-limiting dissection, distal emboliza-
ion, or angiographic thrombus. Clinical success was deﬁned as
ngiographic success without associated in-hospital complications
e.g. death, myocardial infarction (MI), stroke, emergency coronary
rtery bypass graft (CABG)].
moking  status
Patients  were queried about their smoking status and habits at
he time of the procedure and at follow-up. Smoking volume was
xpressed as the number of cigarettes smoked each day. The study
opulation was divided into three groups on the basis of smoking
tatus at time of the index procedure and follow-up: (1) nonsmok-
rs, who did not regularly smoke at any time, or who  had stopped
moking for more than 1 year; (2) quitters, who permanently quit
moking immediately after the index procedure; and (3) persis-
ent smokers, who regularly smoked before their procedure as well
s at any time during the follow-up period. There were no non-
mokers who began to smoke after the index procedure in our
tudy. Whether the patients smoked or not was determined based
n the patients’ self-reported data at the time of the procedure and
ollow-up.
he smoking cessation program and clinical follow-up
All patients undergoing PCI in our hospital were ordered to stop
moking (including active smoking and passive smoking, e.g. sec-
ndhand smoke) when they were in hospital and after discharge.
ur medical staff strongly advised them to cease smoking and
xplained to them the hazards of continued smoking and the bene-
ts of cessation after the index procedure. They were required to go
o hospital regularly for follow-up. The smoking cessation program
ased on a physician’s recommendation for smokers to quit was
erformed. The Ask, Advise, Assess, Assist, and Arrange algorithm
the 5 A’s framework) for smoking cessation was used. Brieﬂy, at
very visit or telephone contact follow-up, ask each patient about
obacco use; advise each smoker to quit; assess each smoker’s will-
ngness to make a quit attempt; assist each smoker in making
 quit attempt by offering medication and referral for counsel-
ng and arrange for follow-up. For relapsers, provide them withogy 62 (2013) 283–288
psychological  support, encourage their close relatives and friends
to take part in smoking cessation programs and offer social support,
and advise them to begin early medical therapy.
Patient follow-up information was obtained from hospital
charts and telephone interview with the patient or their imme-
diate relatives, conducted by a single cardiologist, the end time of
follow-up was June 2012. Major adverse cardiac and cerebrovascu-
lar events (MACCE) were carefully recorded, including death from
any cause, nonfatal MI,  cerebrovascular events (CVE), and coronary
revascularization. All-cause death was  deﬁned as a composite of
death from any cause. Nonfatal MI  was  deﬁned as the presence of
typical chest pain, electrocardiographic ST-segment elevation with
or without Q waves, as well as serum cardiac enzyme elevations
at least 2-fold upper limit of the normal range. CVEs were deﬁned
as stroke and reversible ischemic neurologic deﬁcits, which were
conﬁrmed by computed tomography scanning and adjudicated by
a neurologist. Revascularization was deﬁned as repeat PCI or CABG
during follow-up.
Statistical analysis
Categorical variables were presented by frequency counts, and
the differences were tested using the chi-square test or Fisher exact
test. Continuous data were expressed as means ± SD, and the differ-
ences were analyzed with one-way analyses of variance (One-Way
ANOVA, normal distribution) or Mann–Whitney U test (abnormal
distribution or unequal variances). Cumulative event rates were
evaluated using Kaplan–Meier estimate and compared using a log-
rank test. A multivariable Cox proportional hazards model was  used
to evaluate the association between smoking status and adverse
events after adjustment for baseline and procedural factors that dif-
fered signiﬁcantly among the smoking status groups. Univariable
predictors of adverse events with less than 0.05 of p-value were
allowed to enter the model. We  present the results as hazard ratio
(HR) and 95% conﬁdence intervals (CI) and p-values. A proportional-
hazards model was  developed for each end point by using enter
selection. For categorical variables, statistical signiﬁcance was con-
sidered to be p < 0.05 among the 3 groups and p < 0.0167 between
2 groups. All statistical analyses were performed with SPSS17.0
software (SPSS Inc., Chicago, IL, USA).
Results
Adherence to smoking cessation
Among 656 patients who were followed up for 27.24 ± 6.33
(7–40) months, 430 of them were smokers (65.5%) at the index
procedure, 226 patients (34.5%) were non-smokers. By the end of
the follow-up, there were 147 patients (22.4%), who continued to
smoking, deﬁned as persistent smokers; 283 patients (43.1%) com-
pletely ceased smoking after the procedure, as quitters; while 226
non-smokers remained (34.5%). Hence, the prevalence of persistent
smoking in the study population was 22.4% at follow-up, which
accounted for 34.1% of smokers at the time of PCI. That is, about
one–third of the smokers at the time of the index procedure contin-
ued to smoke at clinical follow-up, while only two-third of smokers
successfully ceased smoking.
Among the persistent smokers, 88 (59.9%) attempted to quit
smoking but failed, and no smoker accepted pharmacotherapy.
But most persistent smokers cut on smoking signiﬁcantly dur-
ing follow-up (24.88 ± 11.64 cigarettes per day vs 13.15 ± 9.29
cigarettes per day, p < 0.001).
Baseline clinical, angiographic, and procedural characteristics
and body mass index at follow-up among the three groups
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Baseline characteristics of all patients and the three indi-
idual groups in this study are shown in Table 1. Persistent
mokers were signiﬁcantly younger, and contributed more to
he clinical phenotypes, such as dyslipidemia. Quitters had less
ypertension, compared to persistent smokers and nonsmokers.
here were no remarkable differences in family history of CHD
nd diabetes among the 3 groups. Medication use among the
hree groups was similar at baseline, persistent smokers less
ook aspirin and statins than quitters and nonsmokers at follow-
p.
Angiographic and procedural characteristics of the three groups
re shown in Table 1. Of all the treated vessels 8 (0.8%)were left
ain coronary artery, 388(59.1%)were left anterior descending
rtery, 178(27.1%)were left circumﬂex artery, and 211(32.2%)were
ight coronary artery. The number of complex type (B2 and C) was
50(68.6%), and the number of ostial and proximal lesions was
76(57.3%). A total of 1053 DESs were implanted, which stood for
n average of 1.6 DESs for each patient. DES diameter and length
anges were 2.5–4.5 mm and 12–38 mm,  respectively. The length
f total stent, the numbers of stents implanted, types and sites
f lesions did not differ signiﬁcantly among the three groups of
atients being investigated.
able 1
he  baselines clinical, angiographic, procedural characteristics and BMI  and medication u
Variables All (n = 656) Nonsmokers (n = 226) 
Age (years) 57.94 ± 11.63 61.04 ± 11.90 
BMI  at baseline 25.63 ± 3.03 25.43 ± 2.94 
BMI  at follow-up 25.53 ± 2.80 25.17 ± 2.69 
BMI  −0.09 ± 2.08 −0.25 ± 2.07 
Hypertension 382(58.2%) 144(63.7%) 
Diabetes  191(29.1%) 75(33.2%) 
Dyslipidemia  320(48.8%) 101(44.7%) 
Previous  MI  74 (11.3%) 22(9.7%) 
Prior  PCI or CABG 50(7.6%) 22(9.7%) 
Family  history of CHD 73(11.1%) 18(8.0%)
SA  15(2.3%) 6(2.7%) 
UA  431(65.7%) 160(70.8%) 
AMI  210(32.0%) 60(26.5%) 
LVEF  (%) 52.32 ± 9.21 51.49 ± 8.50 
Cr  (mol/L) 85.90 ± 36.56 88.78 ± 52.48 
The  number of diseased vessels 1.20 ± 0.42 1.24 ± 0.45 
Multi-vessel  disease 441(67.2%) 152(67.3%) 
Treated  vessel
LM  5(0.8%) 3(1.3%) 
LAD  388(59.1%) 141(62.4%) 
LCX  178(27.1%) 69(30.5%) 
RCA  211(32.2%) 67(29.6%) 
Types  B2 or C of lesions 450(68.6%) 157(69.5%) 
Ostial  or proximal lesions 376(57.3%) 136(60.2%) 
The  number of stents per patient 1.61 ± 0.88 1.65 ± 1.00 
Stent  total length (mm) 36.82 ± 22.73 38.01 ± 25.84 
Reference  vessel diameter (mm)  3.02 ± 0.44 3.00 ± 0.39 
Medication  use at baselines
Aspirin  647(98.6%) 223(98.7%) 
Clopidogrel  656(100%) 226(100%) 
Statin 656(100%) 226(100%) 
ACEI or ARB 383(58.4%) 124(54.9%) 
CCB  172(26.2%) 60(26.5%) 
Beta  blockers 519(79.1%) 181(80.1%) 
Medication  use at follow-up
Aspirin  597(90.7%) 210(92.9%) 
Clopidogrel  115(17.5%) 42(18.6%) 
ACEI  or ARB 208(31.7%) 78(34.5%) 
CCB  141(21.5%) 46(20.4%) 
Statin  480(73.2%) 168(74.3%) 
Beta  blockers 421(64.2%) 153(67.7%) 
BMI  = BMI  at follow-up–BMI at baseline; BMI, body mass index; MI,  myocardial infarct
HD,  coronary heart disease; SA, stable angina; UA, unstable angina; AMI, acute myocardi
AD,  left anterior descending artery; LCX, left circumﬂex artery; RCA, right coronary artery;
CB,  calcium channel blocker.
a Compared to nonsmokers: p < 0.0167.
b Compared to quitters: p < 0.0167.ogy 62 (2013) 283–288 285
Body mass index (BMI) among the three groups was similar
at baseline, however, nonsmokers had a lower BMI  (p < 0.0167)
than quitters at follow-up, and weight gain was  greater for quitters
(p < 0.0167) than for nonsmokers; there was  no signiﬁcant differ-
ence between quitters and persistent smokers.
The effect of smoking status on clinical outcomes at follow-up
During follow-up time, the major clinical events of the three
groups in this study are shown in Table 2 and the Kaplan–Meier
curves are shown in Figs. 1 and 2. Sixteen patients died (7 patients
died from cardiac causes), and more than half of those who  died
from any cause were persistent smokers. The incidence of all-cause
death (6.1% vs 1.8% and 1.1% p = 0.004) and MACCE (15.0% vs 7.1%
and 5.3%, p = 0.002) in persistent smokers were signiﬁcantly higher
than those in nonsmokers and quitters.
As the baseline variables did not well match among the three
groups, a Cox multiple regression analysis model was  developed
controlling for the differences in baseline clinical and angiographic
characteristics. After adjusting for such potentially confounding
variables as age, hypertension, dyslipidemia, taking aspirin and
taking statins during follow-up in the modeling process, smoking
se at follow-up.
Quitters (n = 283) Persistent smokers (n = 147) p-Value
57.58 ± 10.86a 53.84 ± 11.33b <0.001
25.69 ± 3.16 25.62 ± 3.03 0.489
25.74 ± 2.87a 25.67 ± 2.30 0.027
0.05 ± 2.14a −0.12 ± 1.98 0.002
148(52.3%)a 90(61.2%) 0.024
78(27.6%) 38(25.9%) 0.234
130(45.9%) 89(60.5%)a,b 0.005
32(11.3%) 20(13.6%) 0.513
18(6.4%) 10(6.8%) 0.331
35(12.4%) 20(13.6%) 0.162
8(2.8%) 1(0.7%) 0.332
175(61.8%) 96(65.3%) 0.106
100(35.3%) 50(34.0%) 0.090
52.46 ± 9.53 53.33 ± 9.55 0.161
82.72 ± 15.21 87.62 ± 35.63 0.650
1.17 ± 0.41 1.17 ± 0.38 0.085
184(65.0%) 105(71.4%) 0.406
1(0.4%) 1(0.7%) 0.451
165(58.3%) 82(55.8%) 0.416
70(24.7%) 39(26.5%) 0.338
96(33.9%) 48(32.7%) 0.585
200(70.7%) 93(63.3%) 0.275
163(57.6%) 77(52.4%) 0.328
1.64 ± 0.86 1.48 ± 0.71 0.321
37.32 ± 21.97 34.05 ± 18.65 0.402
3.02 ± 0.42 3.05 ± 0.53 0.748
280(98.9%) 144(98.0%) 0.707
283(100%) 147(100%)
283(100%) 147(100%)
164(58.0%) 95(64.6%) 0.171
69(24.4%) 43(29.3%) 0.547
220(77.7%) 118(80.3%) 0.751
262(92.6%) 125(85.0%)a,b 0.016
46(16.3%) 27(18.4%) 0.754
88(31.1%) 42(28.6%) 0.463
64(22.6%) 31(21.1%) 0.819
216(76.3%) 96(65.3%)b 0.045
176(62.2%) 92(62.6%) 0.393
ion; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft;
al infarction; LVEF, left ventricular ejection fraction; LM,  left main coronary artery;
 ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
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Table 2
The  clinical outcomes during follow up among three groups.
Variable All (n = 656) Nonsmokers (n = 226) Quitters (n = 283) Persistent smokers (n = 147) p-Value
Non-fatal MI 2(0.3%) 0(0.0%) 0(0.0%) 2(1.4%) 0.094
All-cause  death 16(2.4%) 4(1.8%) 3(1.1%) 9(6.1%)a,b 0.004
Cardiac  death 7(1.1%) 2(0.9%) 1(0.4%) 4(2.7%) 0.073
Non-cardiac  death 9(1.4%) 2(0.9%) 2(0.7%) 5(3.4%) 0.055
CVE  11(1.7%) 2(0.9%) 6(2.1%) 3(2.0%) 0.518
Revascularization 25(3.8%) 10(4.4%) 6(2.1%) 9(6.1%) 0.101
MACCE  53(8.1%) 16(7.1%) 15(5.3%) 22(15.0%)ab 0.002
M iac and cerebrovascular events.
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a Compared to nonsmokers: p < 0.0167.
b Compared to quitters: p < 0.0167.
tatus was added to complete the multivariate model. Persis-
ent smoking was a predictor of all-cause death (HR = 2.432,
5% CI 1.170–5.054; p < 0.017) and MACCE (HR = 1.519, 95% CI
.049–2.200; p = 0.027). The multivariable adjusted results of all-
ause death and MACCE are shown in Table 3.
iscussion
In this study, we demonstrate, for the ﬁrst time, that in Chinese
ale patients (1) there was high smoking rate at the time of the
ndex intervention and persistent smoking rate at follow-up after
he DES deployment; and (2) although there were some favorable
linical and angiographic features in persistent smokers compared
ith non-smokers and quitters, the formers were at increased risk
f all-cause death and MACCE.
oor adherence to smoking cessation
Smoking is generally thought to have deleterious long-
erm health effects on the cardiovascular system. Therefore, all
uidelines about the prevention and treatment of CHD have rec-
mmended all patients with established CHD should stop smoking,
ncluding active and passive smoking. However, the complete
ig. 1. Survival curves (all-cause death) among different smoking status groups. PCI,
ercutaneous coronary intervention.Fig. 2. MACCE-free survival curves among different smoking status groups. MACCE,
major adverse cardiac and cerebrovascular events; PCI, percutaneous coronary
intervention.
cessation of cigarette smoking is a difﬁcult challenge for patients
after PCI in clinical practice.
In our study, among 656 male patients who were followed up for
an average 27.24 months, 430 of them were smokers at the index
procedure. Thus, the prevalence of active smoking in our survey was
65.5%, similar to that in the general Chinese male population, higher
than the ﬁndings (20–40%) [11–13] reported previously from
Table 3
The  predictive factors of all-cause death and MACCE by multivariable regression.
Variable Hazard ratio 95%  conﬁdence interval p-Value
All cause death
Smoking status 2.432 1.170–5.054 0.017
Age 1.104 1.047–1.165 <0.001
Hypertension 2.557 0.720–9.084 0.147
Dyslipidemia 1.137 0.421–3.070 0.800
Aspirin (follow-up) 0.632 0.159–2.503 0.513
Statin (follow-up) 0.887 0.295–2.670 0.831
MACCE
Smoking status 1.519 1.049–2.200 0.027
Age 1.028 1.003–1.054 0.026
Hypertension 1.479 0.829–2.642 0.185
Dyslipidemia 1.575 0.905–2.740 0.108
Aspirin (follow-up) 0.662 0.291–1.506 0.325
Statin (follow-up) 0.780 0.422–1.441 0.427
MACCE, major adverse cardiac and cerebrovascular events.
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estern countries, and those (54.1%) [16] from our center in 2009.
y the end of follow-up, there were still 147 persistent smokers,
ndicating that persistent smoking rate at follow-up was  still 22.4%.
hat is, only 65.8% smokers at the time of index successfully stopped
moking, which was similar to the previous study in our center, and
he data (62.79–68.1%) from Western countries [3,11–14]. A total of
4.1% of them continued to smoke or relapsed after a period of time
f quitting smoking, suggesting poor compliance with the complete
essation of smoking. Furthermore, the rate of persistent smoking
fter DES deployment was relatively high, compared with the con-
inued smoking rate 11% [17] reported previously by Fernandez
t al., 20.02% [15] in the Taira study, and 17.7% [16] reported by
ur center in 2009. The differences between those previous studies
nd our present study may  be partly attributable to study popu-
ation. Previous studies enrolled subjects of both sexes, whereas
nly male patients were enrolled in our study, because compared
ith most high-income countries, almost all Chinese smokers were
ale. Hence, considering that the effect of smoking on clinical out-
omes may  be diluted if including females, our study only included
ale patients. To our knowledge, it was the only study about Chi-
ese male smokers at present.
In  our study, older patients were more likely to be nonsmok-
rs. Older patients after PCI were more likely to successfully quit
moking, according to the study conducted by Ockene et al. [4].
aybe young smokers after PCI were conﬁdent about their out-
ome, and not overly concerned about the possibility of subsequent
dverse events. Moreover, with the time after PCI prolonged, some
atients tended to think they recovered completely from CHD or
ven thought they were cured, and they began to smoke again.
herefore, wherever in China or Western countries, patients who
moked at time of PCI had poor compliance with smoking cessation.
ardiologists should aggressively promote the complete cessation
f cigarette smoking in their patients, especially in the younger
nes. Taken together, we found that there was a great gap in cessa-
ion of smoking between guideline recommendations and clinical
ractice, particularly in China. The reasons for poor adherence to
moking cessation in Chinese male patients are as follows: Firstly,
moking has become a culture in China, at many social situations,
ffering cigarettes to a friend or the elder is considered a good will
esture; Secondly, China now is at the stage of high-speed eco-
omic development and urbanization; People, especially young
ales have a lot of pressure in their life, and cigarette smoking
s assumed to relieve the stress. Thirdly, most Chinese smokers
eceive less education and cannot have a proper understanding of
moking cessation. Finally, until now there exists no law nation-
ide to ban smoking in public places.
eneﬁts of quitting smoking
Compared  with nonsmokers, persistent smokers were younger,
hich did not predispose them to coronary events. However,
igher mortality and the prevalence of MACCE were found in these
atients with or without Cox multiple regression analysis after
djusting the baseline variables, indicating that continued smoking
fter PCI was a risk factor for those severe cardiac outcomes.
Earlier data from our registry had shown that the incidence of
on-fatal MI  in persistent smokers was higher than that in non-
mokers and quitters [16]. The analysis of our follow-up data at a
ean of 19 months allowed us to conﬁrm the relationship between
moking status and clinical outcomes in patients undergoing suc-
essful PCI with bare metal stent or DES implantation. In the present
tudy, the prevalence of nonfatal MI  tended to increase, suggesting
he detrimental effect of continued smoking after PCI. Importantly,
e demonstrated that persistent smokers had a greater risk of
ll-cause death and MACCE than nonsmokers and quitters dur-
ng follow-up; more than 1/2 of those who died from any causeogy 62 (2013) 283–288 287
were  smokers. A series of data regarding the impact of smoking on
the outcomes of PCI has been reported. Hasdai et al. [11] collected
data from 6600 patients who underwent percutaneous coronary
revascularization with a 16-year follow-up, demonstrating that
persistent smokers had a greater risk of death than nonsmokers
and quitters. Mohiuddin et al. [9] reported that in MI  patients
who underwent 2 years of follow-up, smoking cessation decreased
mortality by 77% and reduced hospital readmissions due to heart
disease by 44%. Similarly Jha et al. [23] reported that smokers lose
at least one decade of life expectancy, as compared with those who
have never smoked. Cessation before the age of 40 years reduces
the risk of death associated with continued smoking by about 90%
and the relative risk of MACCE was  approximately 3-fold greater in
persistent smokers than in quitters, and was  approximately 2-fold
than in nonsmokers [22]. The results of those studies were similar
to our study: continued smoking after PCI was a predictive factor
for all-cause death and MACCE. It was interesting to note the low
rate of MACCE in the nonsmokers and quitters during follow-up,
although weight gain was greater for quitters than for nonsmok-
ers. A possible reason for the results was  that inﬂammatory markers
associated with CHD were shown to return to the similar level of a
nonsmoker at ﬁve years after quitting smoking [5], and that weight
gain following smoking cessation did not attenuate the beneﬁts of
quitting smoking on CHD outcomes [24].
Limitations
There are several limitations in this study. Firstly, all the partic-
ipants were from a single center, studies in more diverse samples
would be needed before generalizing the ﬁndings to patients with
CHD. Secondly, our study was not a randomized clinical trial, and
it was impossible to balance perfectly among the three groups. The
differences in baseline characteristics may  have inﬂuenced clinical
outcomes in various ways, although multi-variable Cox regression
was employed to adjust those factors. Thirdly, the rate of loss to
follow-up was  somewhat high, partly because the Chinese pop-
ulation migrates easily from one place to another due to rapid
development, and it was very difﬁcult to follow each patient in clin-
ical practice. Finally, smoking status was self-reported, and there
was no biochemical veriﬁcation. The possibility might be that some
patients who  continued to smoke may  falsely have claimed quitting
smoking.
Conclusion
In the present study, poor adherence to smoking cessation was
found in Chinese male patients after DES implantation. Persis-
tent smoking signiﬁcantly increases the risk of all-cause death and
MACCE. Therefore, an effective smoking cessation program must
be employed and strictly monitored in clinical practice.
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